The March 2013 Issue of The Burrill Report - 03/12/2013

Burrill & Company Indices
Read More
AstraZeneca to Buy Pearl for up to $1.15B
Deal will strengthen pharma’s respiratory portfolio. Read More
Sourcing Innovation
Podcast: June 10, 2013 Read More
Maxygen to Dissolve
Without options for its sole product, board says best decision is to distribute cash to shareholders. Read More
Pfizer Taps CytomX’s ADC Technology in Cancer
Biotech’s probodies are activated in tumor tissue but remain inert in healthy tissue. Read More
Pfizer Taps CytomX’s ADC Technology in Cancer
Biotech’s probodies are activated in tumor tissue but remain inert in healthy tissue. Read More
Supreme Court Backs DNA Collection in Arrests
Cheek swabs and addition to a national DNA database will become common, Scalia warns. Read More
International Alliance Seeks to Share Genomic and Clinical Data
Groups hope to seize “extraordinary opportunity” and avoid balkanization of information. Read More
Sanofi’s Possible PARP-1 Inhibitor Fails Late-Stage Trial
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
New Class of Antibiotics on the Horizon
At least one compound identified that interferes with protein synthesis quality control. Read More

[Please login to post comments]